[go: up one dir, main page]

MXPA02012072A - Derivados de 4,5-dihidro-tiazol-2-ilamina y su uso como inhibidores de no-sintasa. - Google Patents

Derivados de 4,5-dihidro-tiazol-2-ilamina y su uso como inhibidores de no-sintasa.

Info

Publication number
MXPA02012072A
MXPA02012072A MXPA02012072A MXPA02012072A MXPA02012072A MX PA02012072 A MXPA02012072 A MX PA02012072A MX PA02012072 A MXPA02012072 A MX PA02012072A MX PA02012072 A MXPA02012072 A MX PA02012072A MX PA02012072 A MXPA02012072 A MX PA02012072A
Authority
MX
Mexico
Prior art keywords
dihydro
thiazo
synthase inhibitors
alk
formula
Prior art date
Application number
MXPA02012072A
Other languages
English (en)
Inventor
Claude Guyon
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MXPA02012072A publication Critical patent/MXPA02012072A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)

Abstract

La invencion se refiere a composiciones farmaceuticas que contienen como principio activo una 4,5-dihidro-1,3-tiazol-2-ilamina de la formula (1) en donde: R representa un radical-alk-S-alk-Ar, fenilo o fenilo sustituido por alcoxi o halogeno o bien una de sus sales farmaceuticamente aceptables, a los derivados novedosos de la formula (I) y a su preparacion. Tales compuestos son utiles para prevenir y tratar enfermedades en donde esta involucrada una produccion anormal de monoxido de nitrogeno (NO) por induccion de NO-sintasa inducible (NOS-2).
MXPA02012072A 2000-06-09 2001-06-07 Derivados de 4,5-dihidro-tiazol-2-ilamina y su uso como inhibidores de no-sintasa. MXPA02012072A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0007396A FR2810036B1 (fr) 2000-06-09 2000-06-09 Derives de 4,5-dihydro-1,3-thiazol-2-ylamine, leur preparation et les compositions phamarceutiques les contenant
PCT/FR2001/001759 WO2001093867A1 (fr) 2000-06-09 2001-06-07 Derives de 4,5-dihydro-thiazol-2-ylamine et leur utilisation comme inhibiteurs de no synthase

Publications (1)

Publication Number Publication Date
MXPA02012072A true MXPA02012072A (es) 2004-08-19

Family

ID=8851133

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012072A MXPA02012072A (es) 2000-06-09 2001-06-07 Derivados de 4,5-dihidro-tiazol-2-ilamina y su uso como inhibidores de no-sintasa.

Country Status (27)

Country Link
EP (1) EP1299103B1 (es)
JP (1) JP4171297B2 (es)
KR (1) KR20030017990A (es)
CN (1) CN1441673A (es)
AP (1) AP2002002707A0 (es)
AT (1) ATE305298T1 (es)
AU (2) AU6612301A (es)
BR (1) BR0111543A (es)
CA (1) CA2411572C (es)
DE (1) DE60113686T2 (es)
DK (1) DK1299103T3 (es)
DZ (1) DZ3366A1 (es)
EA (1) EA200300009A1 (es)
EC (1) ECSP024374A (es)
ES (1) ES2246327T3 (es)
FR (1) FR2810036B1 (es)
HR (1) HRP20020971A2 (es)
HU (1) HUP0300996A3 (es)
IL (1) IL153327A0 (es)
MA (1) MA25815A1 (es)
MX (1) MXPA02012072A (es)
NO (1) NO20025885L (es)
NZ (1) NZ522967A (es)
OA (1) OA12285A (es)
PL (1) PL360282A1 (es)
WO (1) WO2001093867A1 (es)
ZA (1) ZA200209770B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063732A1 (en) * 2003-12-23 2005-07-14 Microbia, Inc. Compounds and methods for the treatment of asthma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107771A0 (en) * 1992-11-27 1994-02-27 Wellcome Found Pharmaceutical compositions containing isothiourea derivatives certain such novel compounds and their preparation
CN1077886C (zh) * 1993-10-21 2002-01-16 G·D·瑟尔公司 用作一氧化一氮合酶抑制剂的脒基衍生物
WO1996014842A1 (en) * 1994-11-15 1996-05-23 Merck & Co., Inc. Substituted heterocycles as inhibitors of nitric oxide synthase

Also Published As

Publication number Publication date
NO20025885D0 (no) 2002-12-06
AU2001266123B2 (en) 2007-01-25
IL153327A0 (en) 2003-07-06
ZA200209770B (en) 2004-03-02
WO2001093867A1 (fr) 2001-12-13
HUP0300996A2 (hu) 2003-08-28
OA12285A (en) 2006-05-12
CN1441673A (zh) 2003-09-10
HRP20020971A2 (en) 2005-02-28
DZ3366A1 (fr) 2001-12-13
EP1299103A1 (fr) 2003-04-09
KR20030017990A (ko) 2003-03-04
EA200300009A1 (ru) 2003-04-24
HUP0300996A3 (en) 2006-02-28
MA25815A1 (fr) 2003-07-01
FR2810036B1 (fr) 2004-04-23
NO20025885L (no) 2003-01-29
BR0111543A (pt) 2003-07-01
ATE305298T1 (de) 2005-10-15
JP2003535135A (ja) 2003-11-25
CA2411572A1 (fr) 2001-12-13
FR2810036A1 (fr) 2001-12-14
EP1299103B1 (fr) 2005-09-28
DE60113686D1 (de) 2006-02-09
AP2002002707A0 (en) 2002-12-31
ES2246327T3 (es) 2006-02-16
DK1299103T3 (da) 2006-01-23
AU6612301A (en) 2001-12-17
DE60113686T2 (de) 2006-07-13
CA2411572C (fr) 2009-11-10
PL360282A1 (en) 2004-09-06
ECSP024374A (es) 2003-02-06
JP4171297B2 (ja) 2008-10-22
NZ522967A (en) 2005-07-29

Similar Documents

Publication Publication Date Title
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
SE0104332D0 (sv) Therapeutic agents
MX9504349A (es) Derivados de aroilpiperidina.
IL184687A0 (en) Pharmaceutical compositions containing 1,2-dihydropyridin-2-one derivatives
SG128491A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
AP1541A (en) New thiadazoles and oxadiazoles and their use as phosphodiesterase - 7 inhibitors.
ATE356624T1 (de) Phenoxypropanolamin-derivate, ihre herstellung und therapeutische verwendung
IL136100A0 (en) Biphenylamidine derivatives, prodrugs thereof and pharmaceutical compositions containing the same
WO2003049690A3 (en) Hiv integrase inhibitors
EE200000059A (et) Tetrahüdro-gamma-karboliinid
MXPA02011352A (es) Nuevos derivados de benzofurano.
AU2003223340A8 (en) Certain pharmaceutically useful substituted aminoalkyl heterocycles
IL160874A0 (en) 4-imidazolin-2-one derivatives
DE69828197D1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
BG106152A (en) 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
MXPA02012072A (es) Derivados de 4,5-dihidro-tiazol-2-ilamina y su uso como inhibidores de no-sintasa.
MXPA04000620A (es) Uso de derivados de tiazol para elaboracion de medicamento para tratamiento de enfermedad pulmonar obstructiva cronica.
YU79401A (sh) Derivati 1-trifluorometil-4-hidroksi-7-piperidinil- aminometilhromana
BR9917326A (pt) Composto, processo para produzir um composto, e, composição farmacêutica

Legal Events

Date Code Title Description
FG Grant or registration